+Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63

Y F Wu1, X J Liang, Y Y Liu

  • 1Department of Orthopaedics, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China.

Neoplasma
|September 18, 2010
PubMed
Abstract

Insights

Targeting the protein survivin with antisense oligonucleotides significantly inhibits osteosarcoma cell proliferation and induces apoptosis. This approach down-regulates survivin expression and activates Fas-mediated apoptosis, suggesting a potential therapeutic strategy for osteosarcoma.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Osteosarcoma is a primary bone malignancy.
  • Survivin is implicated in the development and progression of various cancers, including osteosarcoma.
  • Apoptosis and Fas signaling pathways are critical in cancer cell fate.

Purpose of the Study:

  • To investigate the effect of targeting survivin using antisense oligonucleotides on osteosarcoma cell apoptosis and proliferation.
  • To elucidate the mechanism by which survivin influences osteosarcoma progression.

Main Methods:

  • Utilized the osteosarcoma cell line MG-63, which exhibits high survivin expression.
  • Employed MTT assays and flow cytometry to assess apoptosis and proliferation rates.
  • RT-PCR and Western blotting were used to measure survivin and Fas mRNA and protein expression.

Main Results:

  • Antisense oligonucleotides targeting survivin significantly increased apoptosis and inhibited proliferation in MG-63 cells in a dose-dependent manner.
  • Survivin mRNA and protein levels were reduced following transfection with antisurvivin oligonucleotides.
  • Fas mRNA and protein expression were upregulated in a dose-dependent manner, inversely correlating with survivin expression.

Conclusions:

  • Survivin plays a crucial role in osteosarcoma development.
  • Blocking survivin with antisense oligonucleotides inhibits osteosarcoma proliferation and induces apoptosis, potentially via the Fas-mediated pathway.
  • Down-regulation of survivin represents a promising therapeutic strategy for osteosarcoma.